CN104546993A - Pharmaceutical composition for treating dark eye circles and preparation method and use thereof - Google Patents
Pharmaceutical composition for treating dark eye circles and preparation method and use thereof Download PDFInfo
- Publication number
- CN104546993A CN104546993A CN201310506603.4A CN201310506603A CN104546993A CN 104546993 A CN104546993 A CN 104546993A CN 201310506603 A CN201310506603 A CN 201310506603A CN 104546993 A CN104546993 A CN 104546993A
- Authority
- CN
- China
- Prior art keywords
- herba
- pharmaceutical composition
- black
- eyed
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 79
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 239000002994 raw material Substances 0.000 claims abstract description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 54
- 241000510764 Villosa Species 0.000 claims description 24
- 239000002537 cosmetic Substances 0.000 claims description 18
- 239000011347 resin Substances 0.000 claims description 9
- 229920005989 resin Polymers 0.000 claims description 9
- 239000003480 eluent Substances 0.000 claims description 7
- 238000010828 elution Methods 0.000 claims description 6
- 229940021171 curative drug Drugs 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 2
- 238000001179 sorption measurement Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 39
- 239000004615 ingredient Substances 0.000 abstract description 8
- 241001269549 Carpesium divaricatum Species 0.000 abstract description 3
- 240000000230 Chromolaena odorata Species 0.000 abstract description 3
- 244000148137 Patrinia villosa Species 0.000 abstract description 3
- 235000019109 Patrinia villosa Nutrition 0.000 abstract description 3
- 244000146462 Centella asiatica Species 0.000 abstract description 2
- 235000004032 Centella asiatica Nutrition 0.000 abstract description 2
- 241001090408 Strobilanthes Species 0.000 abstract description 2
- 208000010668 atopic eczema Diseases 0.000 abstract description 2
- 235000003365 Ilex pubescens Nutrition 0.000 abstract 1
- 241001100932 Ilex pubescens Species 0.000 abstract 1
- 241001145025 Saussurea involucrata Species 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 208000035753 Periorbital contusion Diseases 0.000 description 41
- 235000002673 Dioscorea communis Nutrition 0.000 description 39
- 241000544230 Dioscorea communis Species 0.000 description 39
- 241001465754 Metazoa Species 0.000 description 21
- 238000012360 testing method Methods 0.000 description 21
- 239000003814 drug Substances 0.000 description 20
- 241000283973 Oryctolagus cuniculus Species 0.000 description 19
- 206010002198 Anaphylactic reaction Diseases 0.000 description 16
- 208000003455 anaphylaxis Diseases 0.000 description 16
- 241000700199 Cavia porcellus Species 0.000 description 15
- 206010015150 Erythema Diseases 0.000 description 15
- 230000036783 anaphylactic response Effects 0.000 description 15
- 238000000034 method Methods 0.000 description 15
- 230000008313 sensitization Effects 0.000 description 14
- 206010070834 Sensitisation Diseases 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 12
- 239000000203 mixture Substances 0.000 description 11
- 239000000758 substrate Substances 0.000 description 11
- 231100000321 erythema Toxicity 0.000 description 10
- 239000000284 extract Substances 0.000 description 10
- 241000196324 Embryophyta Species 0.000 description 9
- 206010030113 Oedema Diseases 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000006071 cream Substances 0.000 description 9
- 239000002085 irritant Substances 0.000 description 9
- 231100000021 irritant Toxicity 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 230000036541 health Effects 0.000 description 8
- 208000012641 Pigmentation disease Diseases 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 7
- 239000011248 coating agent Substances 0.000 description 7
- 238000000576 coating method Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 230000019612 pigmentation Effects 0.000 description 7
- 244000025254 Cannabis sativa Species 0.000 description 6
- 201000004624 Dermatitis Diseases 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 230000036407 pain Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 238000007654 immersion Methods 0.000 description 5
- 230000007794 irritation Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 206010007247 Carbuncle Diseases 0.000 description 4
- 241000133134 Saussurea Species 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000000686 essence Substances 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 230000002949 hemolytic effect Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 206010034754 petechiae Diseases 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- -1 stearic acid monoglycerides Chemical class 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 239000003440 toxic substance Substances 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 3
- 206010058679 Skin oedema Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 230000001804 emulsifying effect Effects 0.000 description 3
- 210000000744 eyelid Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 241000209034 Aquifoliaceae Species 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 241000208838 Asteraceae Species 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 241001090347 Bignoniaceae Species 0.000 description 2
- 241000167550 Centella Species 0.000 description 2
- 206010010741 Conjunctivitis Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 241000735527 Eupatorium Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 206010024642 Listless Diseases 0.000 description 2
- WYQVAPGDARQUBT-FGWHUCSPSA-N Madecassol Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(CC[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O WYQVAPGDARQUBT-FGWHUCSPSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 208000019255 Menstrual disease Diseases 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 206010040914 Skin reaction Diseases 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 241000792902 Valerianaceae Species 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- WYQVAPGDARQUBT-XCWYDTOWSA-N asiaticoside Natural products O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2 WYQVAPGDARQUBT-XCWYDTOWSA-N 0.000 description 2
- 229940022757 asiaticoside Drugs 0.000 description 2
- QCYLIQBVLZBPNK-UHFFFAOYSA-N asiaticoside A Natural products O1C(C(=O)C(C)C)=CC(C)C(C2(C(OC(C)=O)CC34C5)C)C1CC2(C)C3CCC(C1(C)C)C45CCC1OC1OCC(O)C(O)C1O QCYLIQBVLZBPNK-UHFFFAOYSA-N 0.000 description 2
- 208000003464 asthenopia Diseases 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000011512 eye pigmentation Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 229940020947 fluorescein sodium Drugs 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 238000011597 hartley guinea pig Methods 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 230000003118 histopathologic effect Effects 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000000552 rheumatic effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 230000035483 skin reaction Effects 0.000 description 2
- 231100000430 skin reaction Toxicity 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 150000003648 triterpenes Chemical class 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- QZLXCFQVOCEKSX-NOCHOARKSA-N (2s,4r)-1-hexadecanoyl-4-hexadecanoyloxypyrrolidine-2-carboxylic acid Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@@H]1C[C@@H](C(O)=O)N(C(=O)CCCCCCCCCCCCCCC)C1 QZLXCFQVOCEKSX-NOCHOARKSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 241000157280 Aesculus hippocastanum Species 0.000 description 1
- 206010054196 Affect lability Diseases 0.000 description 1
- 241000256846 Apis cerana Species 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 240000002900 Arthrospira platensis Species 0.000 description 1
- 235000016425 Arthrospira platensis Nutrition 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 208000008960 Diabetic foot Diseases 0.000 description 1
- 244000025670 Eleusine indica Species 0.000 description 1
- 235000014716 Eleusine indica Nutrition 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010015946 Eye irritation Diseases 0.000 description 1
- 206010019345 Heat stroke Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 244000134716 Hodgsonia macrocarpa Species 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 235000010254 Jasminum officinale Nutrition 0.000 description 1
- 240000005385 Jasminum sambac Species 0.000 description 1
- 244000178870 Lavandula angustifolia Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- 206010024728 Lividity Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 206010027146 Melanoderma Diseases 0.000 description 1
- 241001508687 Mustela erminea Species 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000025174 PANDAS Diseases 0.000 description 1
- 208000021155 Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection Diseases 0.000 description 1
- 240000000220 Panda oleosa Species 0.000 description 1
- 235000016496 Panda oleosa Nutrition 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 206010070835 Skin sensitisation Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 201000004484 acute conjunctivitis Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000002279 cholagogic effect Effects 0.000 description 1
- 210000000589 cicatrix Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000000490 cosmetic additive Substances 0.000 description 1
- 201000010251 cutis laxa Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- SOROIESOUPGGFO-UHFFFAOYSA-N diazolidinylurea Chemical compound OCNC(=O)N(CO)C1N(CO)C(=O)N(CO)C1=O SOROIESOUPGGFO-UHFFFAOYSA-N 0.000 description 1
- 229960001083 diazolidinylurea Drugs 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000004970 emotional disturbance Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 231100000013 eye irritation Toxicity 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000010135 fructus aurantii immaturus Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 235000010181 horse chestnut Nutrition 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000000554 iris Anatomy 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 206010023683 lagophthalmos Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical class OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- MXXWOMGUGJBKIW-YPCIICBESA-N piperine Chemical compound C=1C=C2OCOC2=CC=1/C=C/C=C/C(=O)N1CCCCC1 MXXWOMGUGJBKIW-YPCIICBESA-N 0.000 description 1
- 229940075559 piperine Drugs 0.000 description 1
- WVWHRXVVAYXKDE-UHFFFAOYSA-N piperine Natural products O=C(C=CC=Cc1ccc2OCOc2c1)C3CCCCN3 WVWHRXVVAYXKDE-UHFFFAOYSA-N 0.000 description 1
- 235000019100 piperine Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229920003053 polystyrene-divinylbenzene Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000004706 scrotum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 231100000370 skin sensitisation Toxicity 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 229950011392 sorbitan stearate Drugs 0.000 description 1
- 229940082787 spirulina Drugs 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a pharmaceutical composition for treating dark eye circles and a preparation method and use thereof. Raw materials of the pharmaceutical composition are all natural active ingredients and are nonirritant to skin. The pharmaceutical composition with a dark eye circle treating effect is prepared from patrinia villosa, strobilanthes affinis, ilex pubescens, incarrillea sinensis, centella asiatica, saussurea involucrata, carpesium divaricatum and eupatorium odoratum, wherein the weight percent of any ingredient is not higher than 30% the overall weight. The raw materials of the pharmaceutical composition disclosed by the invention are simply obtained, and the preparation method is convenient. Proved by clinical trial results, the pharmaceutical composition disclosed by the invention has a good effect on the treatment of the dark eye circles, is nonirritant and non-allergic to the skin, is easily accepted by mass consumers, and has good application prospect and market prospect.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition and preparation method thereof and purposes, particularly a kind of have pharmaceutical composition used for cosmetic for the treatment of black eye effect and preparation method thereof and purposes.
Background technology
Body skin is so that part is the thinnest near the eyes, and melanin activity is very vigorous, adds that the factors such as age growth, external irritant haunt, is easy to occur various problem, and black-eyed appearance is just unavoidable! So-called black eye, be when eye vein blood vessel blood flow rate is too slow, eye part skin red blood cell is supported not enough, in vein blood vessel, carbon dioxide and metabolic waste accumulation are too much, form chronic hypoxia, blood is comparatively dark and formed and be detained and cyanic colours that eye pigmentation is formed at eye or auburn shade.The traditional Chinese medical science claims “ Jian Black-spot ".Clinical manifestation: men and women can fall ill, and female is more than man; Be found in any age, minority was fallen ill from pubarche; The most no conscious sympton of patient; Skin lesion feature is that the skin of upper palpebra inferior presents lividity, boundary clear; Can with psychentonia, face is matt, look wan and sallow, by medical histories such as eyestrain, menoxenia, hyperthyroidisms; Do not have enough sleep, night life is frequent, and smoking and drinking can cause primary disease to be increased the weight of.The natural drug of exploitation treatment black eye better effects if has become the problem in science of medicine scholar and dermatologist general concern.As number of patent application 201110400186.6, disclose in this application and a kind ofly have the Chinese medicine composition, preparation and preparation method thereof of dispelling black eye effect, described compositions is made up of the crude drug of following weight parts proportioning: Radix Astragali 40-60 part, Radix Puerariae 10-30 part, Fructus Aurantii Immaturus 10-30 part, Rhizoma Curcumae Longae 10-30 part.For another example number of patent application 201210245706.5, which disclose a kind of anti-black eye eye cream, its formula comprises following component: jasmine hydrosol 50-60: ermine oil 8-12: Radix Puerariae oil 7-9: olive oil 1-3: little by candle Apis cerana Fabricius 1-2: plant whitening agent 1-2: plant collagen 1-2: antiseptic 0.8-1.2.For another example number of patent application 201210295087.4, which disclose a kind of anti-black eye lipid nanoparticle emulsion and preparation method thereof, described emulsion comprises following component, the mixture 0.5-7.3% of olibanoresin extract, Aesculus hippocastanum L. seed extract, tetrahydrochysene piperine, the mixture 1.0-19.6% emulsifying agent 0.5-11.8% of stearic acid monoglycerides or Vegetable oil lipoprotein or stearic acid monoglycerides and Vegetable oil lipoprotein, antiseptic 0.006-1.3%, surplus is water.For another example number of patent application 201010563016.5, which discloses a kind of black eye whitening wrinkle-resisting frost.Be made up of the diazolidinyl urea of the spirulina maxim extract of the Oleum lavandula angustifolia of the dipalmitoyl hydroxyproline of the coenzyme Q10 of the vitamin E of the Jojoba oil of the sorbitan stearate of the glycerol stearate of the polysorbate-60 of the stearyl alcohol of the water of 70-80%, 5-10% butanediol, 1-3%, 1-3%, 1-3%, 1-3%, 2-6%, 0.5-2%, 0.5-2%, 0.5-2%, 0.1-1%, 0.1-1%, 0.1-1% Maifanitum and 0.1-1%.
In sum, black eye are owing to often staying up late, emotional instability, eye strain, aging, vein blood vessel blood flow rate is too slow, and eye part skin red blood cell is for hypoxgia, in vein blood vessel, carbon dioxide and metabolic waste accumulation are too much, form chronic hypoxia, blood is comparatively dark and formed and remain in a standstill and cause eye pigmentation, namely we " the panda eye " often said.Deep black eye can allow people seem listless, affect image very much, and therefore, the development of new safely and effectively black-eyed product of external curing has good Social and economic benef@.
Summary of the invention
The object of the invention is to overcome weak point of the prior art, a kind of pharmaceutical composition and the preparation technology thereof with the effect for the treatment of black eye are provided.
The pharmaceutical composition with the effect for the treatment of black eye of the present invention, with patrima villosa, Herba Goldffussiae Psilostachydis, Radix Ilicis Pubescentis, Herba speranskiae tuberculatae, Herba Centellae, Herba Saussureae Involueratae, Herba Carpesii Divaricati and Herba Eupatorii Odorati for prepared by raw material, and the weight percentage of any component is all no more than 30% of total amount.
Treating black-eyed pharmaceutical composition, is prepare with the raw material of following mass fraction: patrima villosa 1 ~ 60 part, Herba Goldffussiae Psilostachydis 1 ~ 60 part, Radix Ilicis Pubescentis 1 ~ 60 part, Herba speranskiae tuberculatae 1 ~ 60 part, Herba Centellae 1 ~ 60 part, Herba Saussureae Involueratae 1 ~ 60 part, Herba Carpesii Divaricati 1 ~ 60 part, Herba Eupatorii Odorati 1 ~ 60 part.
Treating black-eyed pharmaceutical composition, is prepare with the raw material of following mass fraction: patrima villosa 1 ~ 50 part, Herba Goldffussiae Psilostachydis 1 ~ 50 part, Radix Ilicis Pubescentis 1 ~ 50 part, Herba speranskiae tuberculatae 1 ~ 50 part, Herba Centellae 1 ~ 50 part, Herba Saussureae Involueratae 1 ~ 50 part, Herba Carpesii Divaricati 1 ~ 50 part, Herba Eupatorii Odorati 1 ~ 50 part.
Preferably, described in there is the pharmaceutical composition for the treatment of black eye effect, be prepare with the raw material of following parts by weight:
Patrima villosa 1 ~ 40 part
Herba Goldffussiae Psilostachydis 1 ~ 40 part
Radix Ilicis Pubescentis 1 ~ 40 part
Herba speranskiae tuberculatae 1 ~ 40 part
Herba Centellae 1 ~ 40 part
Herba Saussureae Involueratae 1 ~ 40 part
Herba Carpesii Divaricati 1 ~ 40 part
Herba Eupatorii Odorati 1 ~ 40 part
Preferably, described in there is the pharmaceutical composition for the treatment of black eye effect, be prepare with the raw material of following parts by weight:
Patrima villosa 2 ~ 35 parts
Herba Goldffussiae Psilostachydis 2 ~ 35 parts
Radix Ilicis Pubescentis 2 ~ 35 parts
Herba speranskiae tuberculatae 2 ~ 35 parts
Herba Centellae 2 ~ 35 parts
Herba Saussureae Involueratae 2 ~ 35 parts
Herba Carpesii Divaricati 2 ~ 35 parts
Herba Eupatorii Odorati 2 ~ 35 parts
Preferably, described in there is the pharmaceutical composition for the treatment of black eye effect, be prepare with the raw material of following parts by weight:
Patrima villosa 8 ~ 30 parts
Herba Goldffussiae Psilostachydis 8 ~ 30 parts
Radix Ilicis Pubescentis 8 ~ 30 parts
Herba speranskiae tuberculatae 8 ~ 30 parts
Herba Centellae 10 ~ 30 parts
Herba Saussureae Involueratae 10 ~ 30 parts
Herba Carpesii Divaricati 10 ~ 30 parts
Herba Eupatorii Odorati 10 ~ 30 parts
Most preferred, be prepare with the raw material of following parts by weight:
Patrima villosa 10 parts
Herba Goldffussiae Psilostachydis 10 parts
Radix Ilicis Pubescentis 10 parts
Herba speranskiae tuberculatae 10 parts
Herba Centellae 10 parts
Herba Saussureae Involueratae 10 parts
Herba Carpesii Divaricati 10 parts
Herba Eupatorii Odorati 10 parts
Most preferred, be prepare with the raw material of following parts by weight:
Patrima villosa 8 parts
Herba Goldffussiae Psilostachydis 8 parts
Radix Ilicis Pubescentis 8 parts
Herba speranskiae tuberculatae 12 parts
Herba Centellae 12 parts
Herba Saussureae Involueratae 12 parts
Herba Carpesii Divaricati 12 parts
Herba Eupatorii Odorati 12 parts
Most preferred, be prepare with the raw material of following parts by weight:
Patrima villosa 8 parts
Herba Goldffussiae Psilostachydis 8 parts
Radix Ilicis Pubescentis 15 parts
Herba speranskiae tuberculatae 15 parts
Herba Centellae 15 parts
Herba Saussureae Involueratae 15 parts
Herba Carpesii Divaricati 15 parts
Herba Eupatorii Odorati 15 parts
Most preferred, be prepare with the raw material of following parts by weight:
Patrima villosa 10 parts
Herba Goldffussiae Psilostachydis 10 parts
Radix Ilicis Pubescentis 10 parts
Herba speranskiae tuberculatae 12 parts
Herba Centellae 12 parts
Herba Saussureae Involueratae 12 parts
Herba Carpesii Divaricati 12 parts
Herba Eupatorii Odorati 12 parts
Most preferred, be prepare with the raw material of following parts by weight:
Patrima villosa 8 parts
Herba Goldffussiae Psilostachydis 8 parts
Radix Ilicis Pubescentis 8 parts
Herba speranskiae tuberculatae 10 parts
Herba Centellae 10 parts
Herba Saussureae Involueratae 15 parts
Herba Carpesii Divaricati 15 parts
Herba Eupatorii Odorati 15 parts
The preparation method with the pharmaceutical composition for the treatment of black eye effect of the present invention, comprises the following steps:
(1) each above-mentioned raw material is placed in volumetric concentration be 20% ~ 80% ethanol soak 2 ~ 48 hours, the ethanol consumption soaked is 10 ~ 200 times of each raw material gross weight, filters, obtains soak;
Preferably, filtration residue is the soak with ethanol 2 ~ 48 hours of 20% ~ 80% again by volumetric concentration, merges the solution after soaking, obtains soak.
(2) soak is concentrated into 2 ~ 5% of original weight amount, concentrated solution macroporous resin adsorption, then uses the ethanol repeatedly eluting of volumetric concentration 5 ~ 95%, collects eluent, is the described pharmaceutical composition with the effect for the treatment of black eye;
Preferably, the volumetric concentration of ethanol is 40% ~ 95%;
Described macroporous resin employing Mitsubishi chemical company take polystyrene-divinylbenzene as the HP825L type macroporous resin of matrix; The method that soak concentrates is conventional concentrating under reduced pressure.
Test proves, the pharmaceutical composition with treatment black eye effect of the present invention, has and waits multiple action, can be used in preparing the curative drug for the treatment of black-eyed cosmetics and skin;
The invention still further relates to a kind of skin care cosmetics, there is described in comprising the pharmaceutical composition for the treatment of black eye effect and the adjuvant of cosmetic field use;
The invention still further relates to a kind of curative drug of skin, comprise the pharmaceutical composition with the effect for the treatment of black eye described in claim and medically acceptable carrier.
Especially may be used for preparation circumference of eyes skin care cosmetics, comprise eye cream, essence, liniment and lotion, but be not limited to above-mentioned dosage form, according to method known in skin care industry field, after aforementioned pharmaceutical compositions is degerming by known method, various different external preparation can be made;
During preparation skin care cosmetics, can by obtained extracting solution compositions, through being evaporated to 10% ~ 50% of original weight amount, obtain composition concentrated solution, mix mutually with the substrate of known cosmetics and medicine or adjuvant, carrier, additive, conventionally be prepared, wherein, described composition concentrated solution accounts for 5% ~ 10% of cosmetics gross weight.
It is gloomy that black eye often show as skin of lower eyelid color, comprises the poor and transparence of the shade of too much pigmentation, cutis laxa and tear groove formation, skin of lower eyelid, affect face appearance.Medical circle is more and more paid attention to mainly coming from beauty treatment circle to black eye and was more and more paid close attention to it in the last few years, although it both can not pose a health risk, also can not cause disease and cause any pathologic to change, but it can have a strong impact on emotion and oneself's impression of individual.Especially a lot of women is seriously perplexed by it, even has influence on their quality of life.Black eye can make people seem tired, sad, listless, and this makes a lot of people will cover up black eye when work and social activity.The traditional Chinese medical science is thought, black eye is caused by deficiency of the kidney, and black is the true qualities of kidney, the fine nourishing by the five internal organs vital essence of eye, and as sexual strain, kidney essense is lost two orders at least and lacked moistening of vital essence, and the black of kidney floats on upper so two orders are without god, black eye.
Root of the present invention it is documented and great many of experiments screening, from a large amount of natural plants, patrima villosa, Herba Goldffussiae Psilostachydis, Radix Ilicis Pubescentis, Herba speranskiae tuberculatae, Herba Centellae, Herba Saussureae Involueratae, Herba Carpesii Divaricati and Herba Eupatorii Odorati has been selected to be raw material, prepare the described pharmaceutical composition with the effect for the treatment of black eye, wherein, described patrima villosa selects the dry herb of Valerianaceae plant Patrinia villosa Juss.; Herba Goldffussiae Psilostachydis selects the dry aerial parts of acanthaceous plant Xiao chicken coop Taraphochlamys affinis (G riff) Bremekhu [Strobilanthesaffinis (Griff) Y.C.Tang]; Radix Ilicis Pubescentis selects the dry root of Aquifoliaceae Holly Radix Ilicis Pubescentis (Ilx pubescensHook.et Am.); Herba speranskiae tuberculatae selects Bignoniaceae Herba Incarvilleae sinensis to draft a document the dry herb of plant Incarrillea sinensis LaM.; Herba Centellae selects the dry herb of Centella samphire Centella asialica (L.); Herba Saussureae Involueratae selects the dried floral of Compositae Genus Saussurea Herba Saussureae Involueratae subgenus herbaceous plant Saussurea involucrate (Kar.et Kir.) Sch.Bip; Herba Carpesii Divaricati is the dry herb of Compositae Carpesium plant Carpesium divaricatum Sieb.et Zucc.; Herba Eupatorii Odorati selects the dry herb of Compositae Eupatorium herbaceos perennial Eupatorium odoratum L..
Root it is documented:
Herba Goldffussiae Psilostachydis is the dry aerial parts of acanthaceous plant Xiao chicken coop Taraphochlamys affinis (G riff) Bremekhu [Strobilanthes affinis (Griff) Y.C.Tang], it is a kind of Guangxi traditional herbal medicine, supplement to the Herbal records that its root can be invigorated blood circulation, removing heat from blood, soothing the liverly rush down wet, reducing swelling and alleviating pain, is clinically at present mainly used in the sick treatment such as acute, chronic hepatitis, jaundice.
Patrima villosa (Phylanthus urinaria L.) is one of source of Herba Patriniae, for the dry whole herb with root of Valerianaceae herbaceos perennial patrima villosa Patrinia villosa Juss., have another name called Herba Sonchi Oleracei, bitter vegetarian, Radix Scrophulariae, be distributed widely in south China each province, because extensively being eaten containing beneficiating ingredients such as several amino acids, vitamin and mineral.Herba Patriniae begins to be loaded in Shennong's Herbal, has heat-clearing and toxic substances removing, promoting diuresis and pus discharge, blood circulation promoting and blood stasis dispelling, effect of tranquilizing mind, is usually used in treating appendicitis, lung pus carbuncle clinically, tuberculosis scrofula, carbuncle sore tumefacting virus, enteritis, dysentery, hepatitis, tonsillitis, eye conjunctivitis, postnatal blood stasis is suffered from abdominal pain, spitting of blood, epistaxis, neurasthenia, heart neurosis etc.Pharmaceutical research shows, Herba Patriniae has antibacterial, antiviral, hepatic cholagogic, the effect such as calmness and leukocyte increasing, and toxic and side effects is minimum.
Radix Ilicis Pubescentis is dry root or the leaf of Aquifoliaceae Holly Radix Ilicis Pubescentis (Ilx pubescens Hook.et Am.), has effect of blood circulation and channel invigorating, reducing swelling and alleviating pain, heat-clearing and toxic substances removing, is the Chinese crude drug that south China is conventional.The chemical constitution study of Radix Ilicis Pubescentis shows it mainly containing the type compound such as triterpene and glycosides, lignanoid, iridoid, and wherein triterpene and glycoside thereof are the main components of Radix Ilicis Pubescentis.Pharmaceutical research display Radix Ilicis Pubescentis has the effect such as anti-artery and vein thrombosis, expansion peripheral blood vessel, anticoagulant, adjustment immune status, clinically, all kinds of preparation of Radix Ilicis Pubescentis is widely used in the various diseases such as treatment coronary heart disease, cerebral thrombosis, thromboangiitis, diabetic foot.
Herba speranskiae tuberculatae is the dry herb that Bignoniaceae Herba Incarvilleae sinensis drafts a document plant Incarrillea sinensis LaM., another name scabies grass, malicious maggot grass, grass of delivering a child.Mainly be distributed in the ground such as Liaoning, Jilin, Hebei, Henan, Shandong, Shaanxi, nature and flavor sweet, acrid, warm, enter lung, liver two warp, have dispel the wind, dehumidify, relaxing muscles and tendons to promote blood circulation, the effect such as pain relieving, be used for the treatment of rheumatic arthralgia, the disturbance of lower legs due to pathogenic cold and dampness, eczema scrotum clinically, the diseases such as sore swollen toxin.
Herba Centellae is the dry herb of Centella samphire Centella asialica (L.), has another name called Glechota longituba (Nakai) Kupr, ground wire grass, Gotu Kola etc.Herba Centellae is the perennial herbaceous plant that crawls, and often crispaturas into bulk, and its stem is elongated, and tuberosity is taken root.Originate in India, be now distributed widely in the torrid zone, the world, subtropical zone district, be mainly distributed in each province on the south the Changjiang river in China.Herba Centellae happiness is born in moistening riverbank, marsh, meadow.TAO Hong-Jing is said: this grass is gained the name with cold and cool, its property Great Cold, therefore named Herba Centellae.Herba Centellae begins to be loaded in Shennong's Herbal, has effect of heat-clearing and toxic substances removing, detumescence dampness removing.For jaundice due to damp-heat, heatstroke diarrhoea, sand Stranguria stranguria with blood, carbuncle sore tumefacting virus, injury from falling down.Pharmacological research shows: Herba Centellae extract has outstanding healing of wound and cicatrix repair, and its reason is that asiaticoside has and promotes collage synthesis and the important function such as new vascular generation, the growth of stimulation granulation in body, so be conducive to wound healing.As continuous administration, containing the preparation of asiaticoside, can prevent wound infection from suppurating on skin wound, shorten wound healing time, skin hardness can be reduced and improve skin-nourishing, the effect of enhancing metabolism.
Herba Saussureae Involueratae is the dried floral of Compositae Genus Saussurea Herba Saussureae Involueratae subgenus herbaceous plant Saussurea involucrate (Kar.et Kir.) Sch.Bip, has another name called Herba Saussureae Involueratae, snow lotus of big bud.Herba Saussureae Involueratae is the distinctive rare Chinese medicine in Xinjiang, and locals Feng Xuelian is " king of BAICAO ", " in medicine superfine product ".Herba Saussureae Involueratae is grown on the above height above sea level of snow line in the high mountain gravel and crack of stone of 2600-4000 rice.All there is distribution at Southern Tianshan north slope, particularly have rich in natural resources in the Ili Prefecture in Xinjiang.In Qing Dynasty's supplementary Amplifications of the Compendium of Materia Medica, the existing record to Herba Saussureae Involueratae, claims Herba Saussureae Involueratae " extremely hot in nature can mend lean sun "." Chinese Herbal Medicine in Xinjiang " claims: " Herba Saussureae Involueratae hardship warm in nature, micro-, function expelling wind and removing dampness ".Show the result of study of Herba Saussureae Involueratae at present, its effective ingredient is mainly flavone compound and polysaccharide.The effects such as Herba Saussureae Involueratae has wind-damp dispelling, restores menstrual flow and invigorates blood circulation, warm palace dissipating blood stasis, tonifying yang and enriching blood, are clinically used for the treatment of the diseases such as rheumatic arthralgia, menoxenia, the cold pain of cold womb lower abdomen, lumbago due to renal deficiency, measles without adequate eruption.In recent years, Herba Saussureae Involueratae receives much attention as the effect of ethnic drug in antiearly pregnancy, defying age and inhibition tumor cell propagation.
Herba Carpesii Divaricati is Compositae Carpesium plant Carpesium divaricatum Sieb.et Zucc., is grown in hill thick grass, is mainly distributed in the ground such as Sichuan, Guizhou, Hunan, Fujian and northeast.Its root and basal part of stem all can hyoscines.Its acrid in the mouth is pained, is cool in naturely nontoxicly commonly used for formula for clearing heat and removing toxicity, treatment flu, wind syndrome of head, have loose bowels, the disease such as laryngopharynx swelling and pain, acute conjunctivitis, carbuncle sore tumefacting virus, blood stasis are hemorrhage.
Herba Eupatorii Odorati is Compositae Eupatorium herbaceos perennial Eupatorium odoratum L., is mainly distributed in the ground such as Guangdong, Hainan, Guangxi, Yunnan, Guizhou (west and south) in China.Herba Eupatorii Odorati all herbal medicine, is also conventional medical herbs among the people in China, has dissipating blood stasis for subsidence of swelling, removing toxic substances, hemostasis and disinsection efficiency, be mainly used in treating swelling and pain by traumatic injury, sore swollen toxin, dermatitis and traumatic hemorrhage.Modern pharmacology research shows that the extract of aircraft blade of grass has and suppresses bacillus pyocyaneus, escherichia coli, staphylococcus aureus, gonococcal activity, and can promote the healing of wound.
At present, there is not yet both at home and abroad the compositions of patrima villosa, Herba Goldffussiae Psilostachydis, Radix Ilicis Pubescentis, Herba speranskiae tuberculatae, Herba Centellae, Herba Saussureae Involueratae, Herba Carpesii Divaricati and Herba Eupatorii Odorati is used for the treatment of black-eyed relevant report.
In sum, black-eyed formation is main relevant with pigmentation and Blood vessel pattern, its reason mainly with some bad life habits as stayed up late, smoking, drink, emotional disturbance and make the situation of applying some make up relevant.Current black eye lack effective external use skin care, beneficial effect of the present invention is according to the black-eyed cause of disease and pathomechanism, consult a large amount of monograph and document, successively screened multiple natural plants, finally filtered out and can effectively treat black-eyed pharmaceutical composition.Drug regimen raw material of the present invention obtains simple, and preparation method is convenient.Clinical test results confirms: medicine composite for curing black eye effect of the present invention has good effect, to no skin irritation and sensitization, is easy to be accepted by consumers in general, has a good application prospect and market prospect.
Foregoing invention content part of the present invention has done detailed description to technical scheme of the present invention, and those skilled in the art can repeat the present invention according to foregoing and obtain technique effect of the present invention.Be further explained content of the present invention below by detailed description of the invention, to make those skilled in the art more clearly understand the present invention, not limitation of the present invention, any equivalent replacement or known change all belong to scope.
Detailed description of the invention
Embodiment 1
At room temperature, get patrima villosa 10 kilograms, Herba Goldffussiae Psilostachydis 10 kilograms, Radix Ilicis Pubescentis 10 kilograms, Herba speranskiae tuberculatae 10 kilograms, Herba Centellae 10 kilograms, Herba Saussureae Involueratae 10 kilograms, Herba Carpesii Divaricati 10 kilograms, Herba Eupatorii Odorati 10 kilograms (totally 80 kilograms), with ethanol 800 kilograms of soak extraction of volumetric concentration 70%, soak time is 24 hours, residue soaks with the ethanol 800 kilograms of volumetric concentration 70% and extracts for 24 hours, then the solution after immersion is merged, after 200 object strainer filterings, concentrating under reduced pressure 20 times, again by macroporous resin on concentrated solution, with the ethanol elution of volumetric concentration 50%, containing effective ingredient required in prescription of the present invention in the eluent collected, i.e. pharmaceutical composition.
Embodiment 2
At room temperature, get patrima villosa 8 kilograms, Herba Goldffussiae Psilostachydis 8 kilograms, Radix Ilicis Pubescentis 8 kilograms, Herba speranskiae tuberculatae 12 kilograms, Herba Centellae 12 kilograms, Herba Saussureae Involueratae 12 kilograms, Herba Carpesii Divaricati 12 kilograms, Herba Eupatorii Odorati 12 kilograms (totally 84 kilograms), with ethanol 1680 kilograms of soak extraction of volumetric concentration 50%, soak time is 24 hours, residue soaks with the ethanol 1680 kilograms of volumetric concentration 50% and extracts for 24 hours, then the solution after immersion is merged, after 200 object strainer filterings, concentrating under reduced pressure 40 times, again by macroporous resin on concentrated solution, with the ethanol elution of volumetric concentration 40%, containing effective ingredient required in prescription of the present invention in the eluent collected, i.e. pharmaceutical composition.
Embodiment 3
At room temperature, get patrima villosa 8 kilograms, Herba Goldffussiae Psilostachydis 8 kilograms, Radix Ilicis Pubescentis 15 kilograms, Herba speranskiae tuberculatae 15 kilograms, Herba Centellae 15 kilograms, Herba Saussureae Involueratae 15 kilograms, Herba Carpesii Divaricati 15 kilograms, Herba Eupatorii Odorati 15 kilograms (totally 106 kilograms), with ethanol 1060 kilograms of soak extraction of volumetric concentration 80%, soak time is 24 hours, residue soaks with the ethanol 1060 kilograms of volumetric concentration 80% and extracts for 24 hours, then the solution after immersion is merged, 25 times are concentrated after 200 object strainer filterings, again by macroporous resin on concentrated solution, with the ethanol elution of volumetric concentration 60%, containing effective ingredient required in prescription of the present invention in the eluent collected, i.e. pharmaceutical composition.
Embodiment 4
At room temperature, get patrima villosa 10 kilograms, Herba Goldffussiae Psilostachydis 10 kilograms, Radix Ilicis Pubescentis 10 kilograms, Herba speranskiae tuberculatae 12 kilograms, Herba Centellae 12 kilograms, Herba Saussureae Involueratae 12 kilograms, Herba Carpesii Divaricati 12 kilograms, Herba Eupatorii Odorati 12 kilograms (totally 90 kilograms), with ethanol 2700 kilograms of soak extraction of volumetric concentration 30%, soak time is 24 hours, residue soaks with the ethanol 2700 kilograms of volumetric concentration 30% and extracts for 24 hours, then the solution after immersion is merged, 50 times are concentrated after 200 object strainer filterings, again by macroporous resin on concentrated solution, with the ethanol elution of volumetric concentration 50%, containing effective ingredient required in prescription of the present invention in the eluent collected, i.e. pharmaceutical composition.
Embodiment 5
At room temperature, get patrima villosa 8 kilograms, Herba Goldffussiae Psilostachydis 8 kilograms, Radix Ilicis Pubescentis 8 kilograms, Herba speranskiae tuberculatae 10 kilograms, Herba Centellae 10 kilograms, Herba Saussureae Involueratae 15 kilograms, Herba Carpesii Divaricati 15 kilograms, Herba Eupatorii Odorati 15 kilograms (totally 89 kilograms), with ethanol 1335 kilograms of soak extraction of volumetric concentration 60%, soak time is 24 hours, residue soaks with the ethanol 1335 kilograms of volumetric concentration 60% and extracts for 24 hours, then the solution after immersion is merged, 30 times are concentrated after 200 object strainer filterings, again by macroporous resin on concentrated solution, with the ethanol elution of volumetric concentration 80%, containing effective ingredient required in prescription of the present invention in the eluent collected, i.e. pharmaceutical composition.
Embodiment 6
Liquid embodiment 1 obtained adopts concentrating under reduced pressure, is concentrated into 10% ~ 50% of original weight amount, obtains pharmaceutical composition concentrated solution, and for the preparation of the black-eyed essence for the treatment of, the percentage by weight of component is as follows:
Production technology: hyaluronate sodium is added to the water dispersed with stirring even, then adds other composition successively, stir in 70 DEG C of situations.
Present pre-ferred embodiments matrix components used is described above, and the present embodiment matrix components used can by the efficacy exertion of pharmaceutical composition of the present invention to the best.But the conventional substrate that can be applicable to cosmetics of other manufacturer production also can be used for the present invention, as long as consumption meets national cosmetic additive amount standard, can not affect effect of the present invention, therefore not enumerate.
The present invention's emulsifying equipment used is the FV-30L FISCO vacuum homogeneous emulsifying machine that Shanghai Frock Fluid Machinery Manufacture Co., Ltd. produces, and it has the functions such as homogenizing, stirring and temperature control.The emulsifying equipment prepared for cosmetics of other manufacturer production also may be used for the present invention, as long as operate in strict accordance with technological parameter of the present invention, all can reach effect of the present invention.
Embodiment 7
The black-eyed clinical experimental study of medicine composite for curing is reported: in following experiment, pharmaceutical composition used is the black-eyed eye cream for the treatment of prepared by the cosmetic formulations of embodiment 6.
1. materials and methods
The routine female patient of case selection 56 of 1.1 black eye patients, 20 ~ 40 years old age, average out to 33 years old, wherein, FitzpatrickIII type skin person 48 example, IV type skin person 8 example.Black eye main manifestations is appearing of inferior palpebral veins, does not do other treatment.Be divided into treatment group (30 example) and matched group (26 is routine) at random, two groups in sex, age, the state of an illness without marked difference.
The eye cream containing pharmaceutical composition of the present invention of 1.2 Therapeutic Method treatment groups is provided by Zhong He International Technology company limited, according to a conventional method eye cream is applied in black eye place, 3 times/day after clean face.Matched group: not containing the eye cream of pharmaceutical composition of the present invention, be also according to a conventional method eye cream is applied in black eye place, 3 times/day after clean face.Treat observe the curative effect after 60 days, carry out therapeutic evaluation, and record untoward reaction.
1.3. parameters for observation on effect and standards of grading: follow up a case by regular visits to after 60 days with treatment before treatment and take pictures, evaluated therapeutic effect by two veteran cosmetologists, focal cleaning rate adopts level Four evaluation criterion, namely fully recovers: black eye disappear and reach 90% ~ 100%; Effective: black eye disappear and reach 70% ~ 89%; Effective: black eye disappear 30% ~ 69%; Invalid: black eye disappear below 30% or without significant change.Effective percentage adds effective adding effectively in recovery from illness.
2. result
Treatment group and matched group have pole significant difference (P < 0.1 improving the curative effect in red blood trace on face patient objective sign, table 1), the eye cream containing pharmaceutical composition of the present invention significantly can improve the black eye of most patient.
A table 1 liang group patient objective sign improves situation
All there is not untoward reaction before and after Product Safety assessment treatment, come off without 1 routine patient.There is not the Adverse Event relevant to the eye cream containing pharmaceutical composition of the present invention in whole research process.
Adopt the pharmaceutical composition with the effect for the treatment of black eye of other embodiment to carry out clinical trial, result also proves to have identical effect.This illustrates that pharmaceutical composition of the present invention treats the desirable external use skin care of black eye at present, and its safety is good, untoward reaction is little, strong adaptability, is worthy of popularization.
Embodiment 8
Treat the skin irritation test research report of black-eyed pharmaceutical composition: by animal experiment, observe that treatment black eye pharmaceutical composition acute ocular of the present invention stimulates, local skin irritant reaction that the intact skin of multiple-contact rabbit and damaged skin produce and anaphylaxis situation.In following experiment, pharmaceutical composition used is the pharmaceutical composition of embodiment 1.
1 animal
16 regular grade adult healthy new zealand rabbits, male and female half and half, 2.5kg ~ 3.5kg, buys in Guangdong Medical Lab Animal Center, and laboratory animal production licence number is SCXK (Guangdong) 2008-0002, the animal quality certification number: Guangdong 2012A016.Raise in Animal House F4 room, general area, new southern Drug safety assessment center (the experimental animal room quality certification number: 0060590.), duration of test, room temperature 20 DEG C ~ 22 DEG C, humidity 40% ~ 67%, illumination 12h/12h round the clock light and shade replaces.
2 methods
(1) according to Ministry of Health of the People's Republic of China " cosmetics health specification (version in 2007) ", adopt consubstantiality self left and right sides matching type, tested rabbit is fixed in rabbit fixed bin, pull open the palpebra inferior of eyes on the right side of test rabbit gently, get 0.1mL pharmaceutical composition to clamp-on in conjunctival sac, and make upper and lower eyelid passive closed 1 second.Left side eye does not process makes own control.After instillation tested material 1,24,48,72h checks rabbit bilateral eyes, and marks to conjunctiva, cornea, iris irritant reaction according to the standards of grading in China's " cosmetics health specification " (version in 2007).To give before tested material 20h and to tested material after 24h apply fluorescein sodium respectively rabbit bilateral eyes checked.Inspection method: by the Fluress of 1% instillation test lagophthalmos, passive closed about 10 seconds, then rinse with normal saline, corneal checked whether that the painted speckle of fluorescein sodium is to judge whether cornea has damage subsequently.
(2) irritant test of intact skin: according to Ministry of Health of the People's Republic of China " cosmetics health specification (version in 2007) ", adopt consubstantiality self left and right sides matching type, prepare before administration: 24h before administration, employing is shaved mao method and is removed family's rabbit back spinal column both sides by hair, the left and right each about 3cm × 3cm of unhairing scope, application area 2.5cm × 2.5cm, not injured skin.Administration: in contrast, pharmaceutical composition (1.0g/ only) is smeared in unhairing district, back, right side to left side bare substrate (normal saline), wraps up, after fixing 4h, clean medicine-feeding part with warm water with clean gauze.Smear 1 every day, continuous 14d.Each remove medicine and again observe erythema and edema before coating, whether coating part has pigmentation, petechia, pachylosis or epidermatic atrophy situation and time of origin and regression time, and erythema and edema to be marked.After last coating, after removal medicine, 30-60min, 24h, 48h and 72h perusal is also recorded and is smeared position with or without the situation such as erythema, edema and pigmentation, petechia, skin emolliency.
(3) irritant test of damaged skin: according to Ministry of Health of the People's Republic of China " cosmetics health specification (version in 2007) ", adopt consubstantiality self left and right sides matching type, before test, 24h cuts off a rabbit back both sides fur, unhairing scope left and right each about 3cm × 3cm, application area 2.5cm × 2.5cm.With blade, standardized groined type is damaged gently, the degree of being with oozing of blood.Then in contrast, pharmaceutical composition (1.0g/ only) is smeared in unhairing district, back, right side, wraps up with clean gauze in left side bare substrate (normal saline) immediately, after fixing 4h, cleans medicine-feeding part with warm water.Smear 1 every day, continuous 14d.Each remove medicine and again observe erythema and edema before coating, whether coating part has pigmentation, petechia, pachylosis or epidermatic atrophy situation and time of origin and regression time, and erythema and edema to be marked.After last coating, after removal medicine, 30-60min, 24h, 48h and 72h perusal is also recorded and is smeared position with or without the situation such as erythema, edema and pigmentation, petechia, skin emolliency.
3 results
(1) result of acute ocular irritation test result table 2 shows the eye irritation of pharmaceutical composition of the present invention to rabbit.Test rabbit right eye is after clamp-oning pharmaceutical composition 0.1mL, and 3 test rabbits all show eye closing, without obvious secretions, without obvious edema.Each time observes eye dripping irritant reaction.Give tested material do not rinse after 1,24,48,72h each time observes eye dripping irritant reaction integration and is 0 point.
A table 2 1.0g/ pharmaceutical composition is to rabbit eyes stimulation
(2) irritant test of intact skin: the result of table 3 shows pharmaceutical composition of the present invention to rabbit intact skin nonirritant.Histopathologic examination's result of the test: matched group and pharmaceutical composition group rabbit skin epithelial cell form no abnormality seen, corium and subcutaneous tissue have no vasodilation and inflammatory cell infiltration and collagen fiber hyperplasia.
A table 3 1.0g/ pharmaceutical composition is to rabbit intact skin stimulation
(3) irritant test of damaged skin: 16 rabbit of pharmaceutical composition group without erythema, without the situation such as edema, pigmentation (table 4).Histopathologic examination's result of the test: matched group and pharmaceutical composition group rabbit skin epithelial cell form no abnormality seen, corium and subcutaneous tissue have no vasodilation, have no obvious collagen fiber hyperplasia, visible mild inflammatory cellular infiltration.Therefore pharmaceutical composition of the present invention is to rabbit damaged skin nonirritant.
A table 4 1.0g/ pharmaceutical composition is to rabbit damaged skin stimulation
Embodiment 10
Treat the hypersensitive experimentation report of black-eyed pharmaceutical composition: by animal experiment, observe treatment black eye pharmaceutical composition of the present invention to the sensitization of Hartley guinea pig skin.The pharmaceutical composition that the pharmaceutical composition used in this experiment is the embodiment of the present invention 1.
1 animal
Select regular grade Hartley Cavia porcellus 50, male and female half and half, weight range 180 ~ 250g, buy in Guangdong Medical Lab Animal Center, laboratory animal production licence number is SCXK (Guangdong) 2008-0002, the animal quality certification number: Guangdong 2012A064.Raise in Animal House F4 room, general area, new southern Drug safety assessment center (the experimental animal room quality certification number: 0060590.), duration of test, room temperature 20 DEG C ~ 22 DEG C, humidity 40% ~ 67%, illumination 12h/12h round the clock light and shade replaces.By number skin dyeing is carried out to Cavia porcellus, with saturated picric acid solution (yellow) dye marker units, with 2% silver nitrate solution (coffee color) dye marker tens; Separately raise by sex, each cage box puts 5 Cavia porcelluss, and cage box is outer labelled, indicates the information such as special topic numbering, animal category, group, sex, route of administration, cage number, number of animals and desired assay commencement date and deadline.The pharmaceutical composition that the pharmaceutical composition used in this experiment is the embodiment of the present invention 1, concentration is 1.0g medicine/only.
2 methods
According to country " drug registration management method ", " Chemical induced irritation, anaphylaxis and hemolytic investigative technique guideline ".Be divided into bare substrate group, positive controls, pharmaceutical composition group at random, wherein bare substrate group 10 Cavia porcelluss, all the other respectively organize 20 Cavia porcelluss.Each group of Cavia porcellus male and female half and half.Successively carry out induction sensitization and contact experiment with exciting, two test between be separated by eluting phase of 10 days.Induction exposure experimental technique is front 24h preserved skin, cut off each 2cm × 2cm region, Cavia porcellus spinal column both sides by hair.Positive controls: get 2.5%2, the acetone soln 0.2g of 4-dinitro-chloro-benzene, cover with two-layer gauze (2.5cm × 2.5cm) and one deck antistaling film respectively, 6h is covered with non-stimulated gauze, remove covering, remove residual given the test agent with warm water, the 7th day and the 14th day, in kind repeat once; Be coated with bare substrate 0.1g in bare substrate treated animal same area, pharmaceutical composition group is coated with 0.1g.Induction exposure is carried out by same step.Contact is excited to be then after last is to tested material sensitization contact 14 days (namely testing the 28th day), at the pharmaceutical composition of pharmaceutical composition group guinea pig back preserved skin place coating 0.1g, package is with fixing, tested material is removed after 6h, observe at once, then again observe skin allergy situation in 24h, 48h and 72h.The positive controls acetone soln 0.2g of 2.5%2,4-dinitro-chloro-benzene, bare substrate treated animal same area is coated with bare substrate 0.1g.1h, 24h and 24h, 48h and 72h observation administration local skin erythema, edema and other abnormal responses after exciting after sensitization.By skin allergy standards of grading, skin erythema and edema are marked, and calculate the anaphylaxis incidence rate of each group, judge anaphylaxis occurrence degree by skin hypersensitivity evaluation criterion.Anaphylaxis incidence rate=(occurring number of animals/this treated animal sum of skin erythema, edema or systemic anaphylaxis in group) × 100%.
3 results:
Excite the rear 24h of contact experiment, 48h and 72h, by not knowing that the professional of experiment content is according to " Chemical induced irritation, anaphylaxis and hemolytic investigative technique guideline " pass judgment on whether occur sensitization of skin reaction (table 5), sensitivity response scoring >=2 timesharing, judge that this animal skin sensitivity response is positive, calculate sensitization rate (>=2 points of number of animals/these treated animal sum × 100%), and by " Chemical induced irritation, anaphylaxis and hemolytic investigative technique guideline " in sensitization of skin reaction test grade scale judge the sensitization intensity (table 6) of pharmaceutical composition of the present invention to guinea pig skin.
Table 5 sensitization of skin extent of reaction standards of grading
First calculate and put each group of integral mean value each observing time, then calculate and to observe in the time limit animal integral mean value every day every, evaluate by " Chemical induced irritation, anaphylaxis and hemolytic investigative technique guideline ".By following formulae discovery every animal average integral every day.
Table 6 sensitization of skin extent of reaction grade scale
Excite rear 24h, 48h and 72h, the Cavia porcellus of bare substrate group, pharmaceutical composition group excites area skin all not occur erythema, edema situation, also do not occur other abnormal response, anaphylaxis incidence rate is 0, and anaphylaxis evaluation is and has no skin allergy (table 7).
Excite rear 6h, 2,4-dinitro-chloro-benzene group Cavia porcellus excites area skin all to occur erythema, and anaphylaxis incidence rate is 100%, and anaphylaxis is evaluated as extremely strong sensitization.Excite rear 48h, 2,4-dinitro-chloro-benzene Cavia porcellus excites area skin still all to have erythema, and anaphylaxis incidence rate is 100%, and anaphylaxis evaluation is still extremely strong sensitization.
The anaphylaxis of table 7 pharmaceutical composition guinea pig skin is marked
4 conclusions
Under this experiment condition, pharmaceutical composition carries out 3 sensitization to Hartley guinea pig skin and has no skin allergy after exciting for 1 time.
Claims (9)
1. treat black-eyed pharmaceutical composition, it is characterized in that: with patrima villosa, Herba Goldffussiae Psilostachydis, Radix Ilicis Pubescentis, Herba speranskiae tuberculatae, Herba Centellae, Herba Saussureae Involueratae, Herba Carpesii Divaricati and Herba Eupatorii Odorati for prepared by raw material, and the weight percentage of any component is all no more than 30% of total amount.
2. treat black-eyed pharmaceutical composition, it is characterized in that, it is prepare with the raw material of following mass fraction: patrima villosa 1 ~ 60 part, Herba Goldffussiae Psilostachydis 1 ~ 60 part, Radix Ilicis Pubescentis 1 ~ 60 part, Herba speranskiae tuberculatae 1 ~ 60 part, Herba Centellae 1 ~ 60 part, Herba Saussureae Involueratae 1 ~ 60 part, Herba Carpesii Divaricati 1 ~ 60 part, Herba Eupatorii Odorati 1 ~ 60 part.
3. the black-eyed pharmaceutical composition for the treatment of according to claim 2, it is characterized in that, it is prepare with the raw material of following mass fraction: patrima villosa 1 ~ 50 part, Herba Goldffussiae Psilostachydis 1 ~ 50 part, Radix Ilicis Pubescentis 1 ~ 50 part, Herba speranskiae tuberculatae 1 ~ 50 part, Herba Centellae 1 ~ 50 part, Herba Saussureae Involueratae 1 ~ 50 part, Herba Carpesii Divaricati 1 ~ 50 part, Herba Eupatorii Odorati 1 ~ 50 part.
4. the preparation method of the black-eyed pharmaceutical composition of the treatment according to any one of claims 1 to 3, is characterized in that, comprise the following steps:
The first step: each above-mentioned raw material is placed in volumetric concentration be 20% ~ 80% ethanol soak, the ethanol consumption soaked is 10 ~ 200 times of each raw material gross weight, filters, obtains soak;
Second step: soak is concentrated into 2 ~ 5% of original weight amount, concentrated solution macroporous resin adsorption, then be the ethanol elution of 5 ~ 95% by volumetric concentration, collect eluent, be the black-eyed pharmaceutical composition of described treatment.
5. the preparation method of the black-eyed pharmaceutical composition for the treatment of according to claim 4, is characterized in that: in the first step, and the described soak with ethanol time is 2 ~ 48 hours; Or each raw material first uses soak with ethanol 2 ~ 48 hours, residue uses soak with ethanol 2 ~ 48 hours again, merges the solution after soaking, obtains soak.
6. the preparation method of the black-eyed pharmaceutical composition for the treatment of according to claim 4, is characterized in that: in second step, and the volumetric concentration of described eluting ethanol is 40% ~ 95%.
7. the purposes of the black-eyed pharmaceutical composition of the treatment according to any one of claims 1 to 3, is characterized in that: for the preparation of the curative drug of skin care cosmetics or skin.
8. skin care cosmetics, comprise the adjuvant that the black-eyed pharmaceutical composition for the treatment of described in any one of claims 1 to 3 and cosmetic field use.
9. the curative drug of skin, comprises the black-eyed pharmaceutical composition for the treatment of described in any one of claims 1 to 3 and medically acceptable carrier.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310506603.4A CN104546993A (en) | 2013-10-18 | 2013-10-18 | Pharmaceutical composition for treating dark eye circles and preparation method and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310506603.4A CN104546993A (en) | 2013-10-18 | 2013-10-18 | Pharmaceutical composition for treating dark eye circles and preparation method and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104546993A true CN104546993A (en) | 2015-04-29 |
Family
ID=53064765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310506603.4A Pending CN104546993A (en) | 2013-10-18 | 2013-10-18 | Pharmaceutical composition for treating dark eye circles and preparation method and use thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104546993A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105534813A (en) * | 2016-01-19 | 2016-05-04 | 佛山市芊茹化妆品有限公司 | Cosmetic composition with dark circle relieving effect and preparation method and application thereof |
| FR3036962A1 (en) * | 2015-06-03 | 2016-12-09 | Infinitus China Co Ltd | COSMETIC COMPOSITION BASED ON CENTELLA ASIATICA |
| CN107865927A (en) * | 2017-09-19 | 2018-04-03 | 广州青岚生物科技有限公司 | A kind of clarification process and method of quality control of the pharmaceutical composition that there are treatment livid ring around eye to act on |
| CN108815309A (en) * | 2018-07-28 | 2018-11-16 | 广州青岚生物科技有限公司 | A kind of pharmaceutical composition for treating eyelet periphery melanin deposition disease |
| CN110051571A (en) * | 2018-09-18 | 2019-07-26 | 广州青岚生物科技有限公司 | A kind of pharmaceutical composition of sun-proof reparation |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101756849A (en) * | 2008-11-12 | 2010-06-30 | 孙延明 | Beauty cream for removing dark eye circles |
| CN102335216A (en) * | 2010-07-14 | 2012-02-01 | 株式会社安露莎 | Inhibitor for generation of melanin |
| CN102475672A (en) * | 2010-11-29 | 2012-05-30 | 吴克 | Under-eye dark circle whitening and wrinkle-resisting cream |
-
2013
- 2013-10-18 CN CN201310506603.4A patent/CN104546993A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101756849A (en) * | 2008-11-12 | 2010-06-30 | 孙延明 | Beauty cream for removing dark eye circles |
| CN102335216A (en) * | 2010-07-14 | 2012-02-01 | 株式会社安露莎 | Inhibitor for generation of melanin |
| CN102475672A (en) * | 2010-11-29 | 2012-05-30 | 吴克 | Under-eye dark circle whitening and wrinkle-resisting cream |
Non-Patent Citations (3)
| Title |
|---|
| 吕即来: "《中医三才医学论》", 31 May 2009 * |
| 董银卯等: "《本草药妆品》", 30 June 2010 * |
| 谢惠英等: ""几种植物提取物在化妆品中的应用现状"", 《香料香精化妆品》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3036962A1 (en) * | 2015-06-03 | 2016-12-09 | Infinitus China Co Ltd | COSMETIC COMPOSITION BASED ON CENTELLA ASIATICA |
| CN105534813A (en) * | 2016-01-19 | 2016-05-04 | 佛山市芊茹化妆品有限公司 | Cosmetic composition with dark circle relieving effect and preparation method and application thereof |
| CN107865927A (en) * | 2017-09-19 | 2018-04-03 | 广州青岚生物科技有限公司 | A kind of clarification process and method of quality control of the pharmaceutical composition that there are treatment livid ring around eye to act on |
| CN108815309A (en) * | 2018-07-28 | 2018-11-16 | 广州青岚生物科技有限公司 | A kind of pharmaceutical composition for treating eyelet periphery melanin deposition disease |
| CN110051571A (en) * | 2018-09-18 | 2019-07-26 | 广州青岚生物科技有限公司 | A kind of pharmaceutical composition of sun-proof reparation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101496844B (en) | External preparation for treating leukoderma and method for preparing and using the same | |
| CN102988264B (en) | Folium Ginkgo freckle removing and whitening frost and preparation method thereof | |
| CN103041173A (en) | Traditional Chinese medicine external preparation for curing dermatitis and eczema and preparing method thereof | |
| CN102049008A (en) | Traditional Chinese medicine composition for treating chloasma and preparation method thereof | |
| JP5646117B2 (en) | Hair growth promoter and production method | |
| KR101128564B1 (en) | The manufacturing process of lithospermum erythrorhizon soap controlled by vineger | |
| CN104546993A (en) | Pharmaceutical composition for treating dark eye circles and preparation method and use thereof | |
| CN105434405A (en) | Eye-protection mask, and preparation method thereof | |
| CN109044941B (en) | Skin firming, nourishing and moisturizing composition and preparation method and application thereof | |
| CN109528500A (en) | A kind of eye sticker composition and preparation method thereof | |
| CN105496917A (en) | Herba centellae anti-wrinkling face cream and preparation method thereof | |
| CN108888563A (en) | A kind of water profit thirst quenching hydra-balance mask and preparation method thereof | |
| CN103041042A (en) | Tibetan medicine composition and application of composition in anti-off hair products | |
| CN109939193A (en) | A kind of composition for treating skin eczema, preparation and preparation method and application | |
| CN106420564A (en) | Cornu cervi pantotrichum external restoration composition | |
| CN109125165A (en) | A kind of compact face of repairing is releived facial mask and preparation method thereof | |
| CN104688627A (en) | Acne eliminating mask | |
| CN106074959A (en) | Black-eyed Chinese medicine composition of a kind of alleviation and preparation method thereof | |
| CN103181961A (en) | Preparation method of flavonoid medicine for treating frostbite | |
| CN104856920A (en) | Sleep facial mask capable of removing acne marks and preparation method of sleep facial mask | |
| CN108403932A (en) | A kind of Chinese medicine compound prescription external preparation and its preparation method and application for treating steroid dependent dermatitis | |
| CN108567852A (en) | A kind of pharmaceutical composition of prevention diabetic neuropathy | |
| CN104547064A (en) | Pharmaceutical composition for treating facial telangiectasis and preparation method and use thereof | |
| CN107362244A (en) | A kind of Eradicates removes the Chinese medical extract and its external preparation of red blood trace on face | |
| CN103505398B (en) | Forsythia leaf facial mask |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20170216 Address after: 510000 Guangdong, Conghua, suburban street, No., cross river road, No. -6 (plant 3) on the third floor of building two Applicant after: Guangzhou Green Biological Technology Co., Ltd. Address before: 510000, Guangzhou, Panyu District, Inner Ring Road West University Hospital building, building, building, building 5, Applicant before: Wang Enhan |
|
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150429 |